Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00403442 · ClinicalTrials.gov registry record · Phase 1
Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD
A Phase 1 study, sponsored by Vitreous -Retina- Macula Consultants of New York.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00403442 is a Phase 1 study that was terminated before completion, run by Vitreous -Retina- Macula Consultants of New York. The registered enrollment target is 10 participants.
The verdict
NCT00403442, a Phase 1 study, was terminated before completion, sponsored by Vitreous -Retina- Macula Consultants of New York.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to explore the combination of PDT with verteporfin at reduced and standard fluence rates, in conjunction with bevacizumab, in the treatment of subfoveal CNV of all subtypes with a high percentage of subretinal hemorrhage (hemorrhage \>50% of total lesion area). To assess the safety of bevacizumab in combination with verteporfin PDT (reduced fluence: 300 mW/cm2) as compared to bevacizumab in combination with verteporfin PDT (standard fluence: 600 mW/cm2) in patients whose neovascular CNV lesions containing \>50% blood.
Interventions
- DEVICE Verteporfin Therapy/ Drug: Bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2006-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00403442
The ClinicalTrials.gov registry entry for NCT00403442 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vitreous -Retina- Macula Consultants of New York, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Verteporfin Therapy/ Drug: Bevacizumab is the first listed.
NCT00403442 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00403442 about?
NCT00403442 is a clinical study titled "Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD". The purpose of this study is to explore the combination of PDT with verteporfin at reduced and standard fluence rates, in conjunction with bevacizumab, in the treatment of subfoveal CNV of all subtypes with a high percentage of subretinal hemorrhage (hemorrhage \>50% of total lesion area). To asses...
What is the current status of trial NCT00403442?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2006-09.
What interventions are being tested in trial NCT00403442?
The interventions under investigation include: Verteporfin Therapy/ Drug: Bevacizumab (DEVICE).
Who is sponsoring clinical trial NCT00403442?
This trial is sponsored by Vitreous -Retina- Macula Consultants of New York, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.